8-K
filed June 17, 2026, 4:05 PM ET
ticker REGN
CIK 0000872589
other
confidence high
sentiment neutral
materiality 0.10
Regeneron shareholders elect Class II directors, approve auditor and advisory compensation at annual meeting
REGENERON PHARMACEUTICALS, INC.
- All five Class II director nominees elected: Goldstein, Poon, Schenkein, Thompson, Zoghbi.
- Ratification of PwC as independent auditor for FY 2026: 102.5M for, 6.4M against, 68.8K abstain.
- Advisory vote on executive compensation approved: 96.5M for, 6.9M against, 105.5K abstain, 5.5M broker non-votes.
- Meeting held June 12, 2026; results reported June 17, 2026.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENERON PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2026-06-12 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes Joseph L. Goldstein, M.D. 72,398,297 30,904,254 170,603 5,543,411 Christine A. Poon 79,409,070 24,004,880 59,204 5,543,411 David P. Schenkein, M.D. 99,241,219 4,180,107 51,828 5,543,411 Craig B. Thompson, M.D. 81,933,651 21,378,567 160,936 5,543,411 Huda Y. Zoghbi, M.D. 100,665,234 2,698,397 109,523 5,543,411
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENERON PHARMACEUTICALS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For: 102,503,788 Against: 6,443,958 Abstain: 68,819
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-12 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-12
Exact text from the filing
Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes: For: 96,469,374 Against: 6,898,268 Abstain: 105,512 Broker Non-Votes: 5,543,411
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.